Garfield Ramdeen, MD
Nephrology · Albuquerque, NMNPI 1922191022
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,064 and has fallen 97.5% since, to $26 in 2023.
Across 114 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- OPKO Pharmaceuticals, LLC$438
- AstraZeneca$296
- Fresenius USA Marketing, Inc.$194
- Otsuka America Pharmaceutical, Inc.$173
- Amgen$150
- Akebia Therapeutics Inc$142
- plus $481 from 12 others
What the payments were for
- Food & beverage$1,875100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| OPKO Pharmaceuticals, LLC | 45 | $438 |
| AstraZeneca(2 entities) | 16 | $296 |
| Fresenius USA Marketing, Inc. | 12 | $194 |
| Otsuka America Pharmaceutical, Inc. | 9 | $173 |
| Amgen | 9 | $150 |
| Akebia Therapeutics Inc | 4 | $142 |
| Baxter Healthcare | 2 | $134 |
| Vifor Pharma, Inc. | 4 | $69 |
| Bard Peripheral Vascular, Inc. | 1 | $68 |
| Mallinckrodt Enterprises LLC | 2 | $34 |
| Shire North American Group Inc | 2 | $33 |
| GSK | 2 | $32 |
| Travere Therapeutics, Inc. | 1 | $26 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Recordati_rare_diseases_inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
How this compares
$1,875 in reported general payments places this provider in the 60th percentile of 68 nephrology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 12 | $2,916 |
| Furosemide | 12 | $178 |
| Losartan Potassium | 13 | $147 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Albuquerque
- Satyaki BanerjeeAlbuquerque$260K
- Christos ArgyropoulosAlbuquerque$32K
- Arun RajasekaranAlbuquerque$32K
- George Vasquez RiosAlbuquerque$25K
- Jayant KumarAlbuquerque$12K
- Luis Madera MarinAlbuquerque$7K
- Hector CastroAlbuquerque$7K
- Chudi AdiAlbuquerque$7K
- Dale EricksonAlbuquerque$6K
- Lei ChenAlbuquerque$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.